Nivolumab plus Ipilimumab in Advanced Melanoma

New England Journal of Medicine - Tập 369 Số 2 - Trang 122-133 - 2013
Jedd D. Wolchok1, Harriet M. Kluger2, Margaret K. Callahan1, Michael A. Postow1, Naiyer A. Rizvi1, Alexander M. Lesokhin1, Neil H. Segal1, Charlotte E. Ariyan1, RuthAnn Gordon1, Kathleen Reed2, Matthew M. Burke2, Anne Caldwell2, Stephanie Anne Kronenberg1, Blessing Agunwamba1, Xiaoling Zhang3, Israel Lowy4, H. David Inzunza4, William F. Feely4, Christine E. Horak4, Quan Hong4, Alan J. Korman5, Jon M. Wigginton4, Ashok Gupta4, Mario Sznol2
1Ludwig Center, Memorial Sloan-Kettering Cancer Center, New York
2Yale University School of Medicine and Smilow Cancer Center, Yale–New Haven Hospital, New Haven, CT
3Dako North America, Carpinteria
4Bristol-Myers Squibb, Princeton, NJ
5Bristol-Myers Squibb, Redwood City

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1126/science.1203486

10.1016/j.cell.2011.02.013

10.1056/NEJMoa1003466

10.1056/NEJMoa1104621

10.1056/NEJMoa1200690

10.1073/pnas.0915174107

Selby M, 2013, J Clin Oncol, 31, Suppl, 10.1200/jco.2013.31.15_suppl.3061

10.1097/00000421-198212000-00014

10.1158/1078-0432.CCR-09-1624

10.1126/scitranslmed.3003689

10.1200/JCO.2008.21.7695

10.1002/cncr.24951

Postow MA, 2012, J Clin Oncol, 30, Suppl, 10.1200/jco.2012.30.15_suppl.8575

10.1002/cncr.23086

10.1200/JCO.2008.17.8954

Robert C, 2009, Oncologist, 14, 848, 10.1634/theoncologist.2009-0028

10.1200/JCO.2009.26.7609

10.1158/1078-0432.CCR-12-2625

10.1056/NEJMoa1200694

10.1128/MCB.25.21.9543-9553.2005

10.1056/NEJMoa1103782

10.1200/jco.2013.31.18_suppl.cra9006

Gordon MS, Hamid O, Powderly J, et al. A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Presented at the Annual Meeting of the American Association of Cancer Research, Washington, DC, April 6–10, 2013.

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 369 Số 2

122-133

Thông tin tác giả